Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.68% $1.150
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 11.55 mill |
EPS: | -2.16 |
P/E: | -0.530 |
Earnings Date: | Jul 11, 2024 |
SharesOutstanding: | 10.04 mill |
Avg Daily Volume: | 1.007 mill |
RATING 2024-04-18 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.530 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -0.530 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.508 (31.15%) $0.358 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 1.080 - 1.220 ( +/- 6.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-17 | Stern Adam K | Buy | 19 607 | Common Stock |
2023-11-17 | Milhous Alison Tjosvold | Buy | 19 607 | Common Stock |
2023-11-17 | Cohen Douglas Jay | Buy | 19 607 | Common Stock |
2023-11-17 | Murphy Keith | Buy | 19 607 | Common Stock |
2023-11-17 | Gobel David | Buy | 19 607 | Common Stock |
INSIDER POWER |
---|
81.58 |
Last 90 transactions |
Buy: 3 116 580 | Sell: 414 691 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.150 (2.68% ) |
Volume | 0.579 mill |
Avg. Vol. | 1.007 mill |
% of Avg. Vol | 57.47 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.